506 related articles for article (PubMed ID: 29915590)
1. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
3. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
[TBL] [Abstract][Full Text] [Related]
4. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
5. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A
CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
[TBL] [Abstract][Full Text] [Related]
11. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.
Ruocco G; Rossi S; Motta C; Macchiarulo G; Barbieri F; De Bardi M; Borsellino G; Finardi A; Grasso MG; Ruggieri S; Gasperini C; Furlan R; Centonze D; Battistini L; Volpe E
Clin Sci (Lond); 2015 Aug; 129(4):291-303. PubMed ID: 25700150
[TBL] [Abstract][Full Text] [Related]
12. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
[TBL] [Abstract][Full Text] [Related]
14. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients.
Di Bari M; Reale M; Di Nicola M; Orlando V; Galizia S; Porfilio I; Costantini E; D'Angelo C; Ruggieri S; Biagioni S; Gasperini C; Tata AM
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916909
[TBL] [Abstract][Full Text] [Related]
17. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
[TBL] [Abstract][Full Text] [Related]
18. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
[TBL] [Abstract][Full Text] [Related]
19. Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis.
de J Guerrero-García J; Rojas-Mayorquín AE; Valle Y; Padilla-Gutiérrez JR; Castañeda-Moreno VA; Mireles-Ramírez MA; Muñoz-Valle JF; Ortuño-Sahagún D
Immunobiology; 2018 Jan; 223(1):135-141. PubMed ID: 29050818
[TBL] [Abstract][Full Text] [Related]
20. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
Losy J; Michałowska-Wender G
Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]